ArticleJournal of neurology2025
Association between antibody status and exacerbation in patients with myasthenia gravis who achieved minimal manifestation or better status.
Article in Journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical implications of a very late presentation in myasthenia gravis: real world experience in a tertiary center.Arquivos de neuro-psiquiatria · 2026Article
- Predictors of exacerbation in myasthenia gravis after minimal symptom expression: a bicenter cohort study.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aimed to investigate the rate of exacerbation and risk factors associated with exacerbation in patients with myasthenia gravis (MG) who had achieved minimal manifestation or better status (MMS).
methodsThis was a single-center retrospective cohort study. This study included patients with MG aged > 15 years who had attained MMS between July 2015 and June 2020. The outcome was defined as exacerbation occurring after the patient had achieved MMS. The enrolled patients were followed up until the outcome occurred or up to 60 months. To account for potential confounding variables, a stratified multivariate Cox proportional hazards model and propensity-score analyses were used.
resultsA total of 238 patients were enrolled in the study, including 199 (83.6%) antibody-positive and 39 (16.4%) double-seronegative patients. Overall, 134 (56.3%) patients experienced exacerbation during the follow-up period, with a median time to the outcome of 33 months. Double seronegativity was associated with a lower risk of exacerbation in the stratified Cox model (hazard ratio [HR] 0.412, 95% confidence interval [CI] 0.225-0.754) and in propensity score analyses (HR 0.501, 95% CI 0.274-0.917 in the adjusted analysis and HR 0.540, 95% CI 0.297-0.982 in the overlap-weighted analysis). Similar results were observed in the sensitivity analysis. Subgroup analyses implied that the presence of thymoma and the performance of thymectomy were identified as negative prognostic factors in seronegative patients.
conclusionMore than half of the patients with MG experienced exacerbation after achieving MMS in this Chinese population. Double seronegativity was an independent protective factor against exacerbations.
Indexed as
Identifiers
41160183What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.